- Home
- ABUS vs OUST Comparison
ABUS vs OUST Comparison
Compare ABUS & OUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- OUST
- Stock Information
- Founded
- ABUS 2005
- OUST 2015
- Country
- ABUS United States
- OUST United States
- Employees
- ABUS N/A
- OUST N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- OUST Industrial Machinery/Components
- Sector
- ABUS Health Care
- OUST Technology
- Exchange
- ABUS Nasdaq
- OUST Nasdaq
- Market Cap
- ABUS 906.7M
- OUST 1.1B
- IPO Year
- ABUS N/A
- OUST N/A
- Fundamental
- Price
- ABUS $4.57
- OUST $20.86
- Analyst Decision
- ABUS Strong Buy
- OUST Strong Buy
- Analyst Count
- ABUS 2
- OUST 6
- Target Price
- ABUS $5.00
- OUST $31.33
- AVG Volume (30 Days)
- ABUS 932.9K
- OUST 3.0M
- Earning Date
- ABUS 11-13-2025
- OUST 11-04-2025
- Dividend Yield
- ABUS N/A
- OUST N/A
- EPS Growth
- ABUS N/A
- OUST N/A
- EPS
- ABUS N/A
- OUST N/A
- Revenue
- ABUS $14,606,000.00
- OUST $137,298,000.00
- Revenue This Year
- ABUS $138.02
- OUST $33.30
- Revenue Next Year
- ABUS N/A
- OUST $36.50
- P/E Ratio
- ABUS N/A
- OUST N/A
- Revenue Growth
- ABUS 116.64
- OUST 30.20
- 52 Week Low
- ABUS $2.71
- OUST $6.34
- 52 Week High
- ABUS $5.10
- OUST $41.65
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- OUST 33.19
- Support Level
- ABUS $4.41
- OUST $23.35
- Resistance Level
- ABUS $4.87
- OUST $25.90
- Average True Range (ATR)
- ABUS 0.24
- OUST 2.48
- MACD
- ABUS -0.01
- OUST -0.99
- Stochastic Oscillator
- ABUS 40.91
- OUST 3.06
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.